Insider buying
~$405K50K sh @ $8.09
Traded Nov 17 · filed 2 days later
Since the trade −0.5% · S&P 500 −5.8% · to Nov 20
Bought within 5% of the 52-week low, RSI 48, 10% under its 200-day average
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
PRTA · NASDAQ · Pharmaceutical Preparations
Prothena Corp Public Ltd (PRTA) · oqro.io/stocks/PRTA · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Baskets of the companies that insiders, members of Congress or funds recently reported buying, each held under a written rule.
$8.22−0.18 (−2.14%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
Yes. Insiders of Prothena Corp Public Ltd (PRTA) filed 11 open-market purchases in the last 90 days; the latest was filed on Nov 19, 2026.
Since 2014, Prothena Corp Public Ltd insiders reported 35 open-market purchases and 386 sales on Forms 4 and 5, with purchases in 7 different years, most recently 2026.
No open-market sale by an insider of Prothena Corp Public Ltd (PRTA) was filed with the SEC in the last 90 days.
No trade in Prothena Corp Public Ltd (PRTA) was disclosed by a member of Congress in the last 12 months.
Prothena Corp Public Ltd's next results are expected on Feb 17, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−18.2% (−$1.83) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
Adjusted close went from $10.05 on Nov 20, 2025 to $8.22 on Nov 20, 2026 (−18.2%). Disclosed in this range: 11 insider trades, 0 pre-arranged insider sales, 0 Congress trades, and 2 13F position changes for 2 quarters ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Dublin 2, L2.
Last 12 months
−18.2%
Market value
$422M
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 7.91M shares sold short (15.4% of shares outstanding), −0.4% vs the previous count, 15.7 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Revenue, fiscal 2025
$9.68M
−92.8% vs the year before
Net income, fiscal 2025
−$244M
A loss for the year
Shares outstanding
51.3M
As of Oct 29, 2026
Insider buying
Traded Nov 17 · filed 2 days later
Since the trade −0.5% · S&P 500 −5.8% · to Nov 20
Bought within 5% of the 52-week low, RSI 48, 10% under its 200-day average
A major shareholder of Prothena Corp Public paid $405K out of pocket for Prothena Corp Public shares. Shares held went up 5% with this purchase.
Insider buying
Traded Nov 9 · filed 1 day later
Since the trade −6.3% · S&P 500 −8.3% · to Nov 20
Bought 24% below the 52-week high, RSI 55, 5% under its 200-day average
A major shareholder of Prothena Corp Public paid $1.19M out of pocket for Prothena Corp Public shares. Shares held went up 17% with this purchase.
Traded Oct 22 – Oct 23, 2026 · largest single transaction ~$819K
Oct 22, 2026~$819K · 100K sh @ $8.19
DetailsOfficial recordOct 23, 2026~$404K · 50K sh @ $8.07
DetailsOfficial recordInsider buying
Traded Oct 13 · filed 2 days later
Since the trade −1.7% · S&P 500 −11.3% · to Nov 20
Bought 27% below the 52-week high, RSI 46, 10% under its 200-day average
A major shareholder of Prothena Corp Public paid $835K out of pocket for Prothena Corp Public shares. Shares held went up 11% with this purchase.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Against the S&P 500 over the year
Since Nov 18, 2025, PRTA is down 20.7% and the index fund is up 4.5%: 25 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much PRTA moves
Beta 1.0 (1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 249 trading days (1 = in step with it).
Written by software from the filings listed below · Oct 26, 2026
3 more points, with the facts they come from, are in OQRO Pro.
Sign up freeInsiders of Prothena Corp Public Ltd reported 35 open-market purchases and 386 sales since 2014; purchases in 7 different years, most recently 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $8.71M11×11 trades | — |
| 2025 | $1.28M1×1 trade | $50.8M3×3 trades |
| 2024 | $1.47M5×5 trades | $170K1×1 trade |
| 2023 | — | $28.5M113×113 trades |
| 2022 | $42.1M2×2 trades | $56.4M102×102 trades |
| 2021 | $34.2M9×9 trades | $13.9M49×49 trades |
| 2017 | $51K1×1 trade | $7.17M28×28 trades |
| 2016 | — | $5.05M32×32 trades |
| 2015 | — | $18.5M53×53 trades |
| 2014 | $331K6×6 trades | $79.8M5×5 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
Funds and stakes
Contracts, lobbying and filings
Company reports, price and press
Revenue
$620K
−74.3% vs the same quarter a year earlier
Free cash flow, last 12 months
—
Cash from operations minus capital spending
Net debt
—
Debt —, cash $271M, at Sep 30, 2026
Net income, last 12 months
−$24M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 5, 2026.
Revenue and earnings history, 15 fiscal yearsEarnings dates and the stock's moves
Who holds it
Things to keep in mind
Fiscal year Jan 1, 2025 to Dec 31, 2025, from the annual report filed Feb 27, 2026. Read the filing
−93% on the year before ($135M)
0.0% on the year before ($50K)
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 5,000 words.
Prothena is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by our deep scientific expertise built over decades of research, we are advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which our ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. These programs include prasinezumab for the potential treatment of Parkinson’s disease and other related synucleinopathies that targets alpha-synuclein in collaboration with Roche.
And 9 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Feb 27, 2026. Revenue lines are the figures the company tags in its filing; OQRO shows a split only when its lines add up to the reported total revenue. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Off-exchange trading: 39.4% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (21.1% on ATS, 18.3% with other brokers), above its 26-week average of 32.1%. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: INTELLIGENT CROSS LLC (14.1%), UBS ATS (12.2%), SIGMA X2 (11.7%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Latest annual report filed Feb 27, 2026, compared with the one filed Feb 27, 2025. Read the filing
We are not currently a party to any material legal proceedings. We may at times be party to ordinary routine litigation incidental to our business. When appropriate in management’s estimation, we may record reserves in our financial statements for pending legal proceedings.
Source: SEC EDGAR, Form 10-K filed Feb 27, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Last results
Nov 5, 2026
Within the 30 days after it, until Dec 5, 2026
Next results, expected
Feb 17, 2027
after the market closes; the date can move until the company confirms it
Purchases after results
51%
18 of 35 insider purchases since 2013 came within 30 days after a results announcement
From Prothena Corp Public Ltd's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Prothena Corp Public Ltd's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.